Redpoint Investment Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Redpoint Investment Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$296K	Sell	709 -101	-12%	-$50.4K	0.04%	460
2022 Q2	$401K	Hold	810	–	–	0.05%	422
2022 Q1	$456K	Sell	810 -187	-19%	-$113K	0.05%	440
2021 Q4	$753K	Buy	997 +184	+23%	+$138K	0.06%	356
2021 Q3	$606K	Hold	813	–	–	0.05%	401
2021 Q2	$524K	Hold	813	–	–	0.04%	440
2021 Q1	$464K	Buy	813 +324	+66%	+$192K	0.04%	451
2020 Q4	$285K	Buy	+489	New	+$278K	0.03%	489

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Redpoint Investment Management's BIO Position: Q3 2022 in Review

Redpoint Investment Management reduced its Bio-Rad Laboratories Class A (BIO) stake by 12% in Q3 2022, selling an estimated $50.4K and leaving 709 shares worth $296K. The position accounts for 0.04% of the portfolio, ranked #460.

Redpoint Investment Management first reported a position in BIO in Q4 2020 and has held it in 8 quarters since. The position peaked at $753K in Q4 2021. 485 funds tracked by Wall St. Rank hold BIO as of Q3 2022.

Redpoint Investment Management held 709 shares of Bio-Rad Laboratories Class A worth $296K as of Q3 2022.
Redpoint Investment Management sold 101 Bio-Rad Laboratories Class A shares in Q3 2022, an estimated $50.4K.
Bio-Rad Laboratories Class A made up 0.04% of Redpoint Investment Management's portfolio in Q3 2022, its #460 holding.
Redpoint Investment Management first reported a position in Bio-Rad Laboratories Class A in Q4 2020 and has held it in 8 quarters since.
Redpoint Investment Management's Bio-Rad Laboratories Class A position peaked at $753K in Q4 2021.
485 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2022.

Based on Redpoint Investment Management's 13F filing for Q3 2022, filed 14 Oct 2022.